NOXXON to Attend the German Fall Conference on September 6 & 7, 2021

The capital market conference for small and mid-cap companies organized by Equity Forum will take place in the form of virtual one-on-one meetings.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, August 25, 2021
Information
Tags: 
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, NOX-A12, Terminology, Merck Sharp & Dohme Federal Credit Union, Immune system, Communication, GLORIA, Brain, Radiation, MGMT, Tumor microenvironment, ESMO, TME, Safety, Patient, Pembrolizumab, Pancreatic cancer, Neoplasm, German Autumn, Pharmaceutical industry, Medical imaging, NOXXON, the GLORIA Study, the OPTIMUS Study, NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY
Geotags: 
Austria, Germany, Europe, SWITZERLAND, US
⚠ generated by AI ↴
Organisation: 
NOXXON, THE GLORIA STUDY, THE OPTIMUS STUDY
Summary
Key Points: 
  • The capital market conference for small and mid-cap companies organized by Equity Forum will take place in the form of virtual one-on-one meetings.
  • The conference aims at bringing together public company representatives across sectors with investors, analysts, financial journalists, intermediaries and financial industry experts.
  • NOXXONs CEO, Aram Mangasarian, will be available for meetings on both conference days.
  • To schedule a meeting please contact the conference organizer or send an email to [email protected] .


Regulatory News:

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced that it will participate in the German Fall conference taking place from September 6 to September 7, 2021. The capital market conference for small and mid-cap companies organized by Equity Forum will take place in the form of virtual one-on-one meetings.

The conference aims at bringing together public company representatives across sectors with investors, analysts, financial journalists, intermediaries and financial industry experts. Around 100 companies will participate in this year's summit to present their equity story. NOXXON’s CEO, Aram Mangasarian, will be available for meetings on both conference days. To schedule a meeting please contact the conference organizer or send an email to [email protected].

About NOXXON

NOXXON’s oncology-focused pipeline acts on the tumor microenvironment (TME) and the cancer immunity cycle by breaking the tumor protection barrier and blocking tumor repair. By neutralizing chemokines in the TME, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. NOXXON’s lead program NOX-A12 has delivered final top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients published at the ESMO conference in September 2020 and in July 2021 the company announced its Phase 2 study, OPTIMUS, to further evaluate safety and efficacy of NOX-A12 in combination with Merck’s Keytruda® and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. NOXXON is also studying NOX-A12 in brain cancer in combination with radiotherapy which has been granted orphan drug status in the US and EU for the treatment of certain brain cancers. GLORIA, a trial of NOX-A12 in combination with radiotherapy in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy has delivered interim data from the first two cohorts showing consistent tumor reductions and objective tumor responses. The company’s second clinical-stage asset NOX-E36 is a Phase 2 TME asset targeting the innate immune system. NOXXON plans to test NOX-E36 in patients with solid tumors. Further information can be found at: www.noxxon.com.

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

Visit NOXXON on LinkedIn and Twitter.

About the GLORIA Study

GLORIA (NCT04121455) is NOXXON’s dose-escalation, phase 1/2 study of NOX-A12 in combination with irradiation in first-line glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy).

About the OPTIMUS Study

OPTIMUS (NCT04901741) is NOXXON’s open-label two-arm phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

Copyright: 
Copyright Business Wire 2021